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Activation of the tissue factor pathway occurs during continu- intensive care unit in terms of hemofilter circuits and staff
ous venovenous hemofiltration. time, but also has implications for the patient because
Background. Activation of the tissue factor pathway occurs the effects on systemic cardiovascular and hematologicalduring continuous venovenous hemofiltration (CVVH). De-
perturbation are unknown. We have previously shownspite adequate exogenous anticoagulation, the occlusion of
that significant amounts of unfractionated heparin areCVVH circuits can occur within minutes to a few hours of use
and is associated with evidence of thrombin generation. Having not cleared across the membrane of the hemofilter, pre-
found no evidence of activation of the contact factor (intrinsic sumably because of its high negative charge, and that
coagulation) pathway during CVVH, we sought to examine local plasma levels fall within the desired therapeuticthe effect of the first episode of CVVH on the tissue factor
range [1]. If adequate exogenous anticoagulation is pro-(extrinsic) pathway of coagulation and thrombin generation.
vided during hemofiltration, alternative mechanismsMethods. Twelve critically ill patients were studied prior to
the commencement of hemofiltration and at regular intervals must be responsible for premature clotting of the hemo-
thereafter until the filter clotted. filter.
Results. Prior to hemofiltration, most patients had increased
In other extracorporeal circuits such as cardiopulmo-levels of plasma tissue factor, thrombin–antithrombin (TAT)
nary bypass, the binding of plasma factor XII to thecomplexes, and tissue factor pathway inhibitor (TFPI); during
hemofiltration, further generation of TAT complexes occurred. surface of the extracorporeal circuit has been implicated
Initially, levels of activated factor VII (FVIIa) fell and TFPI in the activation of the contact system [2, 3]. We postu-
increased, but during the course of hemofiltration, the levels of lated that contact activation could occur on exposure of
TFPI fell and FVIIa increased. Levels of tissue factor increased
blood to the foreign surface of the hemofilter circuit,during CVVH in some patients, but this was not related to the
resulting in activation of the coagulation system withgeneration of FVIIa.
Conclusions. These data indicate that activation of FVII subsequent thrombin and fibrin generation. We tested
occurred during CVVH, which was related to levels of TFPI, this hypothesis [4], but, contrary to our expectations,
but not tissue factor, and was coincidental to thrombin genera- there was no evidence of further activation of the contacttion.
system of coagulation over the lifespan of the hemofilter.
Nonetheless, premature filter clotting was related to low
plasma levels of the naturally occurring anticoagulants
Hemofiltration is a well-established supportive treat-
antithrombin III (ATIII) and heparin cofactor II (HCII)
ment for critically ill patients with acute renal failure.
at the onset of hemofiltration and with increasing throm-
Although hemofilter circuits have an expected lifespan
bin generation as indicated by rising levels of thrombin–
of 48 to 72 hours, they often clot prematurely. This ap-
antithrombin (TAT) complexes.pears to be particularly frequent in acutely ill, unstable
These data suggested that although thrombin was be-patients who may clot their hemofilters within a few
ing generated in the filters that clotted prematurely, thehours of use. This has not only cost implications for the
stimulus for this was not initiated through activation of
the contact system, and these patients may actually have
a reduced thrombin inhibitory capacity prior to hemofil-Key words: continuous venovenous hemofiltration, thrombin, blood
flow, dialysis, anticoagulation, tissue factor. tration. We postulated that the stimulus for this thrombin
generation may come from activation of the tissue factorReceived for publication August 4, 1998
pathway of coagulation.and in revised form November 17, 1998
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The pathway is triggered when tissue factor in the suben- sent (or relative assent) was obtained beforehand. Pa-
dothelium is exposed following vessel trauma or cell tients were excluded if they were receiving aprotinin,
damage, binding plasma factor VII (FVII), or activated required hemodiafiltration rather than hemofiltration, or
FVII (FVIIa). The FVII:TF catalytic complex exerts suf- if discontinuation of hemofiltration was necessary for
ficient protease activity to activate factor X (FX). The any reason other than clotting of the circuit, for example,
activated FX (FXa) then formed can rapidly convert transfer for computerized tomography scan. Clinical and
the FVII:TF complex to FVIIa:TF, thus potentiating the routine hematological and biochemical laboratory inves-
system. The FVIIa:TF complex can also cleave factor tigations were recorded, including underlying condition,
IX to factor IXa, which can then itself activate FX. The circulatory status, and vasoactive drug requirement.
FXa forms a complex with prothrombin and factor V Twelve patients not previously hemofiltered were stud-
(the prothrombinase complex), cleaving prothrombin to ied: six clotted their filters within 24 hours, and six clotted
thrombin. their filters after 24 hours of use. The results of studies
The main effector in controlling tissue factor-mediated of endothelial damage in these patients have been pub-
coagulation is tissue factor pathway inhibitor (TFPI). lished elsewhere [7].
TFPI binds reversibly to the active site of FXa, inhibiting
the protease; this TFPI:FXa complex then interacts with Hemofiltration
FVIIa:TF, forming an inactive quaternary complex [6]. A pumped venovenous hemofiltration system (either
TFPI is present in three circulating pools: bound to lipo- BSM 22 or Prisma; Hospal Ltd., Loughborough, UK)
proteins, contained in platelets, and free in plasma. How- using polyacrylonitrile AN69 hollow-fiber hemofilters
ever, the majority of TFPI is bound to the vascular endo- (Hospal Ltd.) was primed with heparin as recommended
thelium. by the manufacturer. Blood flow through the circuit was
It is possible that during hemofiltration, tissue factor set at 150 to 200 ml/min, and filtrate volumes were re-
may become exposed because of endothelial injury. We moved at a rate of 1000 ml/hr. The replacement fluid
have previously shown an increase in markers of endo- used was either Hemofiltrasol 22 (Gambro Ltd., Sidcup,
thelial injury in some patients during continuous veno- Kent, UK) or Hemosol LG2 (Hospal Ltd.), the amount
venous hemofiltration [7]. Furthermore, although pe- given depending on the patient’s clinical status and the
ripheral blood cells do not constitutively express tissue desired hourly fluid balance. If required, unfractionated
factor, monocytes and endothelial cells contain an induc- heparin (Multiparin; CP Pharmaceuticals Ltd., Wrex-
ible form of tissue factor [8]. Monocyte tissue factor is ham, UK) was infused directly into the circuit prefilter
known to be up-regulated in sepsis [9], and because many
to maintain satisfactory exogenous anticoagulation.
patients undergoing hemofiltration have sepsis, this is
another potential source of tissue factor during hemofil- Sample collection
tration.
Blood samples were taken from the “arterial” limb ofThe aim of this study was to investigate the effect of
the hemofilter circuit at the following times: prefiltrationhemofiltration on activation and control of the tissue
and following commencement of hemofiltration at 15factor pathway. Proteins and inhibitors of the tissue fac-
minutes, 1 hour, 3 to 4 hours, 8 to 12 hours, 24 hours,tor pathway—namely, plasma tissue factor, FVII, FVIIa,
and every 24 hours thereafter until the filter blocked.and TFPI (by both immunologic and functional assays)—
Whole blood was collected into plastic tubes containingwere studied during the first episode of hemofiltration
0.106 m tri-sodium citrate (9 volumes blood:1 volumein critically ill patients. Thrombin formation was assessed
anticoagulant), EDTA Vacutainers (Becton Dickinsonby measuring TAT complexes and exogenous anticoagu-
Ltd., Cowley, Oxford, UK) or was allowed to clot inlation by an anti-Xa amidolytic assay for heparin. Base-
plain glass tubes for serum. Citrated plasma and serumline levels and changes during hemofiltration in these
were separated by centrifugation at 2000 3 g for 15variables were related to (a) the filter lifespan and (b)
minutes at room temperature, removed, aliquoted intothrombin generation.
plastic tubes, and then frozen at 2708C. The ethylenedi-
aminetetraacetic acid (EDTA) sample was used for a full
METHODS blood count estimation using a Coulter STAKS counter
Patients (Coulter Electronics Ltd., Luton, Bedfordshire, UK).
Patients with acute renal failure requiring continuous
Measurement of hemostatic factorsvenovenous hemofiltration (CVVH) on the intensive
Commercially available solid-phase enzyme-linkedcare unit of University College London Hospitals were
immunosorbent assays (ELISA) were used to measurestudied. Ethical permission to undertake the study was
tissue factor (American Diagnostica Inc., Greenwich,obtained from the joint UCL/UCLH Committee on the
Ethics of Human Research, and informed patient con- CT, USA), total TFPI (American Diagnostica Inc.), and
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TAT complexes (Behring Diagnostics Ltd., Hounslow, 24 hours. Eight of the 12 patients were septic. Eight
had acute respiratory distress syndrome, and eight wereMiddlesex, UK).
Amidolytic substrate assays were used to measure thrombocytopenic prior to hemofiltration (Table 2).
heparin, FVII, and TFPI. The TFPI assay was modified
Thrombin generationfrom Sandset et al, based on its ability to inhibit
FVIIa:TF activation of factor X in the presence of factor The distribution of the variables studied was non-
Gaussian; therefore, all results are represented by theXa as previously described [10, 11]. A two-stage amidoly-
tic assay for factor VII (FVII) was modified from that median (first and third quartiles). TAT complexes were
elevated [14.40 (11.73 to 20.90) mg/liter] in all patientsof Seligsohn et al and was automated using a Sysmex CA-
6000 random access analyzer (Sysmex UK Ltd., Milton prior to hemofiltration (Table 2). In 8 of the 12 patients,
there was a further increase in TAT complexes over theKeynes, UK) as previously described [12, 13]. FVII and
TFPI assays were standardized using Reference Plasma filter lifespan [13.71 (8.14 to 17.98) baseline vs. 26.20
(19.07 to 28.74) prior to clotting, P 5 0.018]. In the four100% (Immuno Ltd., Sevenoaks, Kent, UK). Heparin
was assayed using an antifactor Xa amidolytic substrate patients in which there was no further increase in TAT,
the filter remained patent for longer than 24 hours. Theassay (Uniteste Heparin; Unicorn Diagnostics Ltd.,
London, UK) standardized using unfractionated heparin increase in TAT complexes over the lifespan of the filter
inversely correlated with the filter running time (Fig. 1).(Multiparin; CP Pharmaceuticals Ltd.).
FVIIa was assayed according to the method of Mor-
Activation and inhibition of the tissue factor pathwayrissey et al using a recombinant mutant (truncated) form
of tissue factor that had selectively lost its ability to Tissue factor levels were increased in eight patients
prior to hemofiltration (Table 2). During hemofiltrationpromote factor VII activation while retaining its cofactor
function for the FVIIa-catalyzed activation of factor X there were further increases in plasma tissue factor in
six subjects. The percentage change in tissue factor was[14]. To standardize for other hemostatic factors that
significantly correlated with the percentage of change inmay influence the clotting time, test plasmas were diluted
TAT complexes over the lifespan of the filter (r 5 0.49,1/10 in factor VII-deficient plasma (Diagnostic Reagents
P 5 0.02) and inversely correlated with filter lifespanLtd., Thame, Oxon, UK). The assay was performed using
(r 5 20.72, P 5 0.03).an ACL-300 coagulometer (Instrumentation Laboratory
Baseline FVIIa and FVII levels were below the refer-Ltd., Warrington, Cheshire, UK) and standardized using
ence range in three and four subjects, respectively, priorhuman FVIIa (Novo Nordisk Ltd., Bagsvaerd, Den-
to commencement of hemofiltration (Table 2). Levelsmark). We have previously established that unfraction-
of FVIIa were not correlated with either TFPI or FVIIated heparin up to a plasma concentration of 1 IU/ml
prior to hemofiltration. After 15 minutes of filtration,does not affect this assay [11].
there was a significant decrease in FVIIa followed by an
Statistical analysis increase over the lifespan of the filter (Fig. 2). The in-
crease in FVIIa during hemofiltration did not correlateChanges in variables over the period of filtration were
with either TAT complex generation, the percentageassessed using the Wilcoxon rank test between prefiltra-
increase in tissue factor, or filter lifespan. FVII levelstion levels and those prior to clotting. Correlation be-
did not change significantly during hemofiltration. Pre-tween variables was assessed using Spearman’s rank co-
filtration total TFPI levels measured by both amidolyticefficient of correlation. A P value of less than 0.05 was
and immunologic assays were above the reference rangeconsidered statistically significant.
in 7 out of 12 patients, three of whom (subjects 1, 5,
7) were receiving heparin therapy/prophylaxis prior to
RESULTS institution of hemofiltration (Table 2). However, one
The characteristics of the 12 patients studied are patient receiving heparin therapy prior to institution of
shown in Table 1. Patients had not been previously fil- hemofiltration had normal baseline levels of TFPI (sub-
tered during their intensive care unit admission and re- ject 3). There was a good correlation between amidolytic
ceived unfractionated heparin as an anticoagulant at a and enzyme-linked immunosorbent assays for total TFPI
rate of 500 to 1000 IU/hr. The lifespan of the filter was at baseline (r 5 0.80, P 5 0.0076).
not related to prefiltration levels of any of the hemostatic After 15 minutes of filtration, TFPI levels were signifi-
parameters studied nor to plasma heparin levels. Mono- cantly increased in most patients (Fig. 3), except in two
cyte, neutrophil, and platelet counts as well as the hema- patients who had received heparin prior to hemofiltra-
tocrit did not significantly change during hemofiltration. tion (subjects 5 and 7). The percentage increase in TFPI
Unless otherwise stated, baseline levels of the variables was not significantly correlated with plasma heparin con-
studied were not significantly different between patients centrations. TFPI levels then gradually decreased over
the period of filtration such that, prior to the filter clot-with a filter lifespan of less than 24 hours and more than
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Table 1. Patient characteristics
Vasopressor/ Filter life
No. Age Sex Precipitating condition ARDS inotropes Sepsis hours Outcome
1 65 M Aspiration pneumonia 1 1 1 38 died
2 36 F Rhabdomyolysis 28 to epilepsy 1 2 2 6 survived
3 54 M Post-CABG, sternal wound infection, pancreatitis 2 1 1 4 died
4 52 M Sigmoid volvulus 2 2 2 15 survived
5 50 M Chest infection post-Whipples procedure 1 1 1 30 died
6 74 M Pneumonia/sepsis 1 1 1 28 died
7 65 F Pneumonia 1 1 1 16 died
8 75 M Sepsis post-laproscopy 2 1 1 12 died9
9 61 F Post-CABG heart failure, arrhythmias 1 1 2 18 died
10 42 M Lymphoma/sepsis 1 1 1 68 died
11 29 M Pancreatitis 2 2 2 41 survived
12 77 M Rhabdomyolysis 28 to epilepsy 1 1 1 48 survived
Abbreviations are: CABG, coronary artery bypass graft; ARDS, acute respiratory distress syndrome. Used with permission from reference 7.
Table 2. Prefiltration levels of coagulation variables
Subject TAT TF FVII FVIIa TFPI am TFPI ag PLTS
1 5.99 333 1.01 1.62 3.15 102 78
2a 15.08 208 0.38 0.63 2.79 153 176
3a 7.29 108 0.69 0.33 1.23 38 640
4a 13.71 380 1.05 3.96 2.94 148 104
5 13.27 968 0.40 1.62 4.70 153 37
6 12.75 601 0.70 2.11 1.86 49 48
7a 10.71 446 1.09 2.23 3.93 123 321
8a 44.42 598 0.10 0.16 3.17 109 21
9a 108.44 ,15 0.11 0.60 0.86 59 28
10 18.95 336 0.48 1.82 1.77 57 174
11 17.78 19 0.71 0.34 1.08 42 67
12 22.84 1492 0.81 0.87 2.44 100 73
NR 1.00-4.10 ,220 0.45-1.45 0.60-5.90 0.40-1.90 14-60 150-400
Units mg/liter pg/ml U/ml ng/ml U/ml ng/ml 109/liter
Abbreviations are: NR, normal range; TAT, thrombin-antithrombin complex; FVII, factor FVII; FVIIa, activated factor VII; TF, tissue factor; TFPI, tissue factor
pathway inhibitor; am, by amidolytic assay; ag, by immunological assay; Plts; platelets.
a Filter life , 24 hours
ting, plasma TFPI levels were not significantly different ingly, an increase in TAT complexes has been found
to prefiltration levels (Fig. 3). This decrease in TFPI during hemodialysis in patients with acute renal failure,
was significantly correlated to the percentage increase but not with chronic renal failure [15]. All patients in
in FVIIa over the lifespan of the filter (r 5 0.67, P 5 this study were in acute renal failure.
0.027). Plasma tissue factor levels were increased in most pa-
tients prior to hemofiltration commencement. Plasma
tissue factor levels are increased in disseminated intra-DISCUSSION
vascular coagulation (DIC) [19–22], malignancy [21],
Thrombin–antithrombin complex levels were in-
vasculitis [20], and chronic renal failure [20, 21]; however,creased in all patients prior to hemofiltration, suggesting
the clinical relevance of these observations are not fullyan underlying degree of coagulation activation. TAT
understood. Tissue factor is a trans-membrane proteincomplexes are known to be increased in patients with
and requires phospholipid for its FVII-dependent coagu-sepsis [15, 16] and chronic renal failure [16–18]. Further
lant activity. The cellular origin of soluble plasma tissueincreases in TAT complexes over the lifespan of the
factor is unclear, and it is not known whether this solublefilter were seen in most patients; in those not showing
form can support the activation of coagulation. It is possi-a rise, the filter remained patent for longer than 24 hours.
ble that plasma tissue factor is derived from endothelialThe rise in TAT complex levels was inversely corre-
cell injury [23] or activated monocytes. However, in-lated with filter lifespan. This confirms the results of our
creased plasma tissue factor levels are not observed inprevious study [4], namely, that activation of coagulation
sepsis, a syndrome known to increase monocyte tissuewith subsequent thrombin generation occurs during he-
mofiltration and is related to filter occlusion. Interest- factor expression [20, 21].
Cardigan et al: Coagulation during hemofiltration1572
Fig. 3. Total tissue factor pathway inhibitor (TFPI) levels prior to
hemofiltration, after 15 minutes of hemofiltration, and prior to the
hemofilter clotting. The horizontal line indicates the median, the box
the interquartile range, and the bars the 95% confidence interval
(N 5 12). NS, not significant; P 5 0.029 by the Wilcoxon rank test.
Fig. 1. Correlation between the increase in thrombin–antithrombin mains speculative, but in this study, it is unlikely given(TAT) complexes during hemofiltration and filter lifespan. P 5 0.0436
that the increase in tissue factor during hemofiltrationby the Spearman’s correlation (N 5 12; r 5 20.61).
was not related to the degree of FVII activation.
If increased baseline levels of TAT complexes seen in
the subjects studied here were due to increased activa-
tion of the tissue factor pathway, one might expect to
observe increased levels of FVIIa prior to hemofiltration.
However, this was not the case. Indeed, some patients
had low levels of FVIIa at baseline. In other clinical
situations in which there may be enhanced activation of
the tissue factor pathway, such as DIC and sepsis, FVIIa
levels are normal or decreased [25, 26]. The latter authors
suggest that the low levels of FVIIa observed may be due
to increased turnover, binding of FVIIa to cell-associated
tissue factor, impaired synthesis, or increased proteolytic
degradation. After 15 minutes of hemofiltration, plasma
FVIIa levels were significantly decreased compared with
baseline. This coincided with an increase in plasma TFPI
Fig. 2. Activated factor VII (FVIIa) levels prior to hemofiltration, after at this time point. Because TFPI is the main inhibitor15 minutes of hemofiltration, and prior to the hemofilter clotting. The
of the FVIIa:TF complex, this is not surprising. However,horizontal line indicates the median, the box the interquartile range,
and the bars the 95% confidence interval (N 5 12). *P 5 0.0022 by after this initial decrease, FVIIa levels then increased
the Wilcoxon rank test. over the lifespan of the hemofilter until the filter oc-
cluded, suggesting activation of FVII during this period.
The increase in FVIIa during hemofiltration coincided
with the generation of TAT complexes, although no sig-Some patients in this study showed a marked increase
nificant correlation existed between them. This indicatesin plasma tissue factor during the period of hemofiltra-
that activation of FVII over this period does not solelytion that correlated with an increase in TAT complexes.
mediate thrombin generation.Others have reported that levels of TAT complex and
Likewise, there was no correlation between the in-soluble thrombomodulin (a marker of endothelial dys-
crease in FVIIa and the increase in plasma tissue factorfunction) are correlated in hemodialysis patients [24].
during hemofiltration, suggesting that activation of FVIIThis implies that thrombin generation may be responsi-
is not mediated by endothelial dysfunction in these pa-ble for the endothelial dysfunction seen in these patients
tients. Others have shown that levels of FVIIa are in-or, alternatively, that plasma tissue factor may enhance
creased in nondialyzed patients with chronic renal failurethe generation of thrombin. Whether plasma tissue fac-
tor could be mediating the generation of thrombin re- and that this may be mediated by endothelial damage
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[24, 27]. However, further increases in FVIIa seen in to control TF/FVIIa adequately under basal conditions,
patients who are dialyzed were not related to endothelial but when the stimulus is overwhelming (for example,
cell injury, and in both groups, plasma tissue factor did severe trauma or sepsis), it is insufficient. Conversely,
not correlate with FVIIa [24, 27]. infusion of TFPI ameliorates DIC induced by endotoxin
Total TFPI levels were increased prior to hemofiltra- in rabbits [36] and decreases mortality in a baboon model
tion in most patients. TFPI levels are known to be en- of E. coli septic shock [37].
hanced in sepsis [28], DIC [22], and acute respiratory In summary, prior to hemofiltration, most of the pa-
distress syndrome [29]. This may reflect mobilization of tients in this study had (a) increased levels of plasma
TFPI caused by endothelial damage. However, several tissue factor, (b) evidence of thrombin generation, and
of the patients were receiving heparin therapy prior to (c) increased levels of TFPI. In most patients, there was
hemofiltration, and heparin induces a rapid and substan- a further generation of thrombin during hemofiltration,
tial release of TFPI from the endothelium [30]. Nonethe- which inversely correlated with the filter lifespan. Ini-
less, baseline TFPI levels correlated with soluble tissue
tially, there was a fall in FVIIa levels, presumably be-
factor, suggesting that the observed increased levels of
cause of the heparin-induced release of TFPI at this timeTFPI may be due to endothelial injury. After 15 minutes
point. As TFPI levels decreased over the lifespan of theof hemofiltration, there was an increase in TFPI levels
filter, activation of FVII occurred, but this was not re-in most patients, presumably because of the release of
lated to endothelial dysfunction. The generation ofTFPI by heparin. Of the four patients who received hepa-
thrombin was not related to baseline levels of any of therin therapy prior to hemofiltration, there were further
parameters studied. Although thrombin generation wasincreases in TFPI during hemofiltration in two, but not
coincidental to activation of FVII during hemofiltration,in two others. From 15 minutes after starting filtration
there was no significant correlation between them.to the time of filter occlusion, TFPI levels decreased.
The mechanism by which FVII becomes activated dur-At this point, they were not significantly different from
ing hemofiltration is not clear from these results. It doesbaseline levels. The percentage increase in FVIIa corre-
not appear to be related to endothelial cell activation.lated to the percentage decrease in total TFPI from 15
minutes of filtration to prior to the filter clotting. This It is possible that in septic patients, increased expression
indicates that FVII activation can occur during hemofil- of monocyte tissue factor could promote FVII activation.
tration in the face of falling TFPI levels. The mechanisms by which thrombin is generated during
Repeated or continuous infusion of heparin is known hemofiltration are likely to be multifactorial. Decreased
to deplete intravascular pools of TFPI [31]. In septic levels of naturally occurring anticoagulants may reduce
patients, it is possible that if the amount of TFPI bound the inhibitory capacity against thrombin. Increased acti-
to the endothelium is already reduced, a continuous infu- vation and reduced inhibition of the tissue factor path-
sion of heparin will quickly deplete this intravascular way may contribute to thrombin generation, but it is
pool of TFPI. Without increased TFPI levels, if the stim- possible that other atypical stimuli may also be impor-
ulus for tissue factor-induced coagulation is enhanced, tant, such as the activation of coagulation factors on cell
activation of FVII could occur. Although the maximal surfaces. The direct activation of factor X on the surface
rise in TFPI generally mirrored plasma heparin concen-
of monocytes has been shown to occur during cardiopul-
trations, this correlation was not significant. However,
monary bypass [38]. A similar phenomenon may occurTFPI released during hemofiltration may not be due
during hemofiltration, which could contribute to the ob-entirely to heparin, as some TFPI may be released as a
served thrombin generation.result of endothelial injury [7].
Plasma TFPI activity is increased in uremic patients
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The role of TFPI in controlling coagulation in vivo is APPENDIX
illustrated by animal models; immunodepletion of TFPI
Abbreviations used in this article are: CVVH, continuous venove-in rabbits produced DIC following low doses of tissue
nous hemofiltration; FVII, factor VII; FVIIa, activated factor VII; FX,
factor or endotoxin, which were ineffectual in normal factor X; FXa, activated factor X; TAT, thrombin-antithrombin; TF,
tissue factor; TFPI, tissue factor pathway inhibitor.animals [34, 35]. Normal levels of TFPI may thus be able
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